作者: Ana Sofia Rodrigues , Sandro L. Pereira , Marcelo Correia , Andreia Gomes , Tânia Perestrelo
DOI: 10.1371/JOURNAL.PONE.0135617
关键词:
摘要: Background Pluripotent embryonic stem cells grown under standard conditions (ESC) have a markedly glycolytic profile, which is shared with many different types of cancer cells. Thus, some therapeutic strategies suggest that pharmacologically shifting towards an oxidative phenotype, using glycolysis inhibitors, may reduce aggressiveness. Given the metabolic parallels between and stemness would chemotherapeutical agents effect on pluripotency, could strategy involving these be envisioned to modulate cell fate in accessible manner? In this manuscript we attempted determine effects 3-bromopyruvate (3BrP) pluripotency. Although it has other intracellular targets, compound potent inhibitor enzymes thought important maintain profile. The goal was also if contribute influence differentiation.